ANDREW LEVIN

Andrew Levin, Managing Partner at RA Capital, is a highly respected figure in the healthcare investment landscape. His leadership at RA Capital Management, a leading multi-stage investment firm, underscores his profound impact on the biotechnology and life sciences sectors. As a Managing Partner, Andrew Levin is instrumental in shaping RA Capital's investment strategy and overseeing its diverse portfolio. RA Capital is renowned for its dedicated focus on evidence-based drug, medical device, and life science tool companies. Levin's role involves identifying groundbreaking opportunities, conducting rigorous due diligence, and guiding investments across both public and private markets. His expertise helps drive the firm's mission to support companies developing transformative solutions for unmet medical needs.

Andrew Levin's investment focus primarily revolves around biotechnology and pharmaceuticals, though his purview extends to the broader life sciences ecosystem. He is deeply committed to understanding the scientific underpinnings of new therapies and technologies, ensuring that RA Capital invests in companies with strong scientific merit and significant potential for patient impact. This includes early-stage ventures pioneering novel drug discovery platforms as well as more mature companies bringing innovative medical devices to market. His strategic insights are critical in navigating the complex and rapidly evolving healthcare landscape.

Levin's journey in healthcare investment is marked by extensive experience and a deep understanding of the industry. He joined RA Capital in 2004, contributing significantly to its growth and success over nearly two decades. Before his tenure at RA Capital, he honed his analytical skills as a healthcare analyst at Fidelity Investments, a role that provided him with a robust foundation in financial analysis and market dynamics within the healthcare sector. His academic background includes an AB in Biology from Harvard College, providing him with a strong scientific grounding that complements his financial acumen.

While specific individual investments directly attributable solely to Andrew Levin are often not publicly detailed, his leadership as a Managing Partner means he is deeply involved in many of RA Capital's significant investments. RA Capital has a track record of backing numerous successful biotech and life science companies, contributing to advancements in areas like oncology, rare diseases, immunology, and gene therapy. Levin's strategic guidance helps the firm identify and support companies that are poised to make substantial contributions to global health. His involvement ensures that RA Capital continues to be a pivotal force in funding the next generation of healthcare innovation.